I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

A key magnet is China's industrial system, which is the most comprehensive on a global scale and offers unparalleled supply ...

China's economy demonstrated remarkable resilience and adaptability in 2024, amid complex domestic and global landscapes. The ...

Winners of 2024 DEI Employer® Awards. 2024 DEI Employer® Awards. 2024 DEI Employer® Awards & Top 100 DEI Employer® SHANGHAI, CHINA, January 6, 2025 /EI ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. The rights will be transferred from ...

RTW Biotech added that last Monday, Corxel said it acquired worldwide rights to an oral small molecule glucagon-like peptide-1 receptor agonist known as CX11 from Suzhou, China-based Vincentage Pharma ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Cytokinetics, Inc. announced that Sanofi will acquire exclusive rights to aficamten from Corxel Pharmaceuticals for the treatment of hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten ...

But another geographic deal — like the one Cytokinetics recently struck with Bayer in Japan and with Corxel/Sanofi in Greater China — hasn't been disclosed. Aficamten, a small-molecule tablet ...

Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy. Read my CYTK ...